Table of Contents

1 Study Coverage

• 1.1 Cancer Vaccine Product
• 1.2 Market Segments
• 1.3 Key Manufacturers Covered
• 1.4 Market by Type
  • 1.4.1 Global Cancer Vaccine Market Size Growth Rate by Product
  • 1.4.2 Preventive vaccines
  • 1.4.3 Therapeutic vaccines
• 1.5 Market by End User
  • 1.5.1 Global Cancer Vaccine Market Size Growth Rate by End User
  • 1.5.2 Prostate Cancer
  • 1.5.3 Cervical Cancer
  • 1.5.4 Others
• 1.6 Study Objectives
• 1.7 Years Considered

2 Executive Summary

• 2.1 Global Cancer Vaccine Market Size
  • 2.1.1 Global Cancer Vaccine Revenue 2014-2025
  • 2.1.2 Global Cancer Vaccine Sales 2014-2025
• 2.2 Cancer Vaccine Growth Rate by Regions
  • 2.2.1 Global Cancer Vaccine Sales by Regions
  • 2.2.2 Global Cancer Vaccine Revenue by Regions

3 Breakdown Data by Manufacturers

• 3.1 Cancer Vaccine Sales by Manufacturers
  • 3.1.1 Cancer Vaccine Sales by Manufacturers
  • 3.1.2 Cancer Vaccine Sales Market Share by Manufacturers
  • 3.1.3 Global Cancer Vaccine Market Concentration Ratio (CR5 and HHI)
• 3.2 Cancer Vaccine Revenue by Manufacturers
  • 3.2.1 Cancer Vaccine Revenue by Manufacturers (2014-2019)
  • 3.2.2 Cancer Vaccine Revenue Share by Manufacturers (2014-2019)
• 3.3 Cancer Vaccine Price by Manufacturers
• 3.4 Cancer Vaccine Manufacturing Base Distribution, Product Types
  • 3.4.1 Cancer Vaccine Manufacturers Manufacturing Base Distribution, Headquarters
  • 3.4.2 Manufacturers Cancer Vaccine Product Type
  • 3.4.3 Date of International Manufacturers Enter into Cancer Vaccine Market
• 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Product

• 4.1 Global Cancer Vaccine Sales by Product
• 4.2 Global Cancer Vaccine Revenue by Product
• 4.3 Cancer Vaccine Price by Product

5 Breakdown Data by End User

• 5.1 Overview
• 5.2 Global Cancer Vaccine Breakdown Data by End User

6 North America

• 6.1 North America Cancer Vaccine by Countries
  • 6.1.1 North America Cancer Vaccine Sales by Countries
  • 6.1.2 North America Cancer Vaccine Revenue by Countries
  • 6.1.3 United States
  • 6.1.4 Canada
  • 6.1.5 Mexico
• 6.2 North America Cancer Vaccine by Product
• 6.3 North America Cancer Vaccine by End User

7 Europe

• 7.1 Europe Cancer Vaccine by Countries
  • 7.1.1 Europe Cancer Vaccine Sales by Countries
  • 7.1.2 Europe Cancer Vaccine Revenue by Countries
  • 7.1.3 Germany
  • 7.1.4 France
  • 7.1.5 UK
  • 7.1.6 Italy
  • 7.1.7 Russia
• 7.2 Europe Cancer Vaccine by Product
• 7.3 Europe Cancer Vaccine by End User

8 Asia Pacific

• 8.1 Asia Pacific Cancer Vaccine by Countries
  • 8.1.1 Asia Pacific Cancer Vaccine Sales by Countries
  • 8.1.2 Asia Pacific Cancer Vaccine Revenue by Countries
  • 8.1.3 China
  • 8.1.4 Japan
  • 8.1.5 Korea
  • 8.1.6 India
  • 8.1.7 Australia
  • 8.1.8 Indonesia
  • 8.1.9 Malaysia
  • 8.1.10 Philippines
  • 8.1.11 Thailand
  • 8.1.12 Vietnam
  • 8.1.13 Singapore
• 8.2 Asia Pacific Cancer Vaccine by Product
• 8.3 Asia Pacific Cancer Vaccine by End User

9 Central & South America

• 9.1 Central & South America Cancer Vaccine by Countries
  • 9.1.1 Central & South America Cancer Vaccine Sales by Countries
  • 9.1.2 Central & South America Cancer Vaccine Revenue by Countries
  • 9.1.3 Brazil
• 9.2 Central & South America Cancer Vaccine by Product
• 9.3 Central & South America Cancer Vaccine by End User

10 Middle East and Africa

• 10.1 Middle East and Africa Cancer Vaccine by Countries
  • 10.1.1 Middle East and Africa Cancer Vaccine Sales by Countries
  • 10.1.2 Middle East and Africa Cancer Vaccine Revenue by Countries
  • 10.1.3 GCC Countries
  • 10.1.4 Turkey
  • 10.1.5 Egypt
  • 10.1.6 South Africa
• 10.2 Middle East and Africa Cancer Vaccine by Product
• 10.3 Middle East and Africa Cancer Vaccine by End User

11 Company Profiles

• 11.1 Dendreon Corporation
  • 11.1.1 Dendreon Corporation Company Details
  • 11.1.2 Company Business Overview
  • 11.1.3 Dendreon Corporation Cancer Vaccine Sales, Revenue and Gross Margin (2014-2019)
  • 11.1.4 Dendreon Corporation Cancer Vaccine Products Offered
  • 11.1.5 Dendreon Corporation Recent Development
• 11.2 NeoStem Oncology
  • 11.2.1 NeoStem Oncology Company Details
  • 11.2.2 Company Business Overview
  • 11.2.3 NeoStem Oncology Cancer Vaccine Sales, Revenue and Gross Margin (2014-2019)
  • 11.2.4 NeoStem Oncology Cancer Vaccine Products Offered
  • 11.2.5 NeoStem Oncology Recent Development
• 11.3 ImmunoGen
  • 11.3.1 ImmunoGen Company Details
  • 11.3.2 Company Business Overview
  • 11.3.3 ImmunoGen Cancer Vaccine Sales, Revenue and Gross Margin (2014-2019)
  • 11.3.4 ImmunoGen Cancer Vaccine Products Offered
  • 11.3.5 ImmunoGen Recent Development
• 11.4 Inovio Pharmaceuticals
  • 11.4.1 Inovio Pharmaceuticals Company Details
  • 11.4.2 Company Business Overview
  • 11.4.3 Inovio Pharmaceuticals Cancer Vaccine Sales, Revenue and Gross Margin (2014-2019)
  • 11.4.4 Inovio Pharmaceuticals Cancer Vaccine Products Offered
  • 11.4.5 Inovio Pharmaceuticals Recent Development
• 11.5 Novartis
  • 11.5.1 Novartis Company Details
  • 11.5.2 Company Business Overview
  • 11.5.3 Novartis Cancer Vaccine Sales, Revenue and Gross Margin (2014-2019)
  • 11.5.4 Novartis Cancer Vaccine Products Offered
  • 11.5.5 Novartis Recent Development

12 Future Forecast

• 12.1 Cancer Vaccine Market Forecast by Regions
  • 12.1.1 Global Cancer Vaccine Sales Forecast by Regions 2019-2025
  • 12.1.2 Global Cancer Vaccine Revenue Forecast by Regions 2019-2025
• 12.2 Cancer Vaccine Market Forecast by Product
  • 12.2.1 Global Cancer Vaccine Sales Forecast by Product 2019-2025
  • 12.2.2 Global Cancer Vaccine Revenue Forecast by Product 2019-2025
• 12.3 Cancer Vaccine Market Forecast by End User
• 12.4 North America Cancer Vaccine Forecast
• 12.5 Europe Cancer Vaccine Forecast
• 12.6 Asia Pacific Cancer Vaccine Forecast
• 12.7 Central & South America Cancer Vaccine Forecast
• 12.8 Middle East and Africa Cancer Vaccine Forecast

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

• 13.1 Market Opportunities and Drivers
• 13.2 Market Challenges
• 13.3 Market Risks/Restraints
• 13.4 Macroscopic Indicators

14 Value Chain and Sales Channels Analysis

• 14.1 Value Chain Analysis
• 14.2 Cancer Vaccine Customers
• 14.3 Sales Channels Analysis
  • 14.3.1 Sales Channels
  • 14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix

• 16.1 Research Methodology
  • 16.1.1 Methodology/Research Approach
  • 16.1.2 Data Source
• 16.2 Author Details

Cancer vaccines are biological response modifiers. These vaccines work by stimulating or restoring the immune system’s ability to fight against infections and diseases. It is used either as stand-alone therapies or in combination with traditional cancer therapeutics such as chemotherapy and surgery. As cancer is often associated with high mortality rate and are resistant to traditional treatments like chemotherapy and radiation, this has led to the research and development of anti-cancer immunotherapies. The side effects of cancer vaccines may differ from person to person. The most commonly reported are inflation at the site of injection, fever, chills, nausea, blood pressure, and among others.
The global Cancer Vaccine market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Cancer Vaccine market based on company, product type, end user and key regions.

This report studies the global market size of Cancer Vaccine in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Cancer Vaccine in these regions.
This research report categorizes the global Cancer Vaccine market by top players/brands, region, type and end user. This report also studies the global Cancer Vaccine market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Dendreon Corporation
NeoStem Oncology
ImmunoGen
Inovio Pharmaceuticals
Novartis

Market size by Product
Preventive vaccines
Therapeutic vaccines
Market size by End User
Prostate Cancer
Cervical Cancer
Others

Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa

The study objectives of this report are:
To study and analyze the global Cancer Vaccine market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Cancer Vaccine market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Cancer Vaccine companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Cancer Vaccine submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

In this study, the years considered to estimate the market size of Cancer Vaccine are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025

This report includes the estimation of market size for value (million US$) and volume (MT). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Cancer Vaccine market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.